IMMUNIC, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • July 17th, 2019 • Immunic, Inc. • Pharmaceutical preparations • New York
IMMUNIC, INC. (formerly known as Vital Therapies, Inc. (“Vital Therapies”)), a Delaware corporation (the “Company,” with all references in this agreement to the “Company” also referring to Vital Therapies prior to the date on which, pursuant to the terms of the Exchange Agreement, dated as of January 6, 2019, among Vital Therapies, Immunic AG (“Former Immunic”) and the former shareholders of Former Immunic, the shareholders of Former Immunic exchanged all of their shares for shares of common stock of Vital Therapies, resulting in Former Immunic becoming a wholly-owned subsidiary of Vital Therapies; and in connection therewith, Vital Therapies changed its name to Immunic, Inc.), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
IMMUNIC, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 17th, 2019 • Immunic, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [______], by and between Immunic, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
CONTRACT OF EMPLOYMENT between Immunic AG, represented by the Chairman of the Supervisory Board - hereinafter referred to as the "Company“ - and Mr. Daniel Vitt, - hereinafter referred to as the "Management Board“ - Scope and dutiesImmunic, Inc. • July 17th, 2019 • Pharmaceutical preparations
OPTION AND LICENSE AGREEMENT FOR THE LICENSING AND DEVELOPMENT OF [***] INHIBITORSOption and License Agreement • July 17th, 2019 • Immunic, Inc. • Pharmaceutical preparations
This LICENSE AND OPTION AGREEMENT FOR THE LICENSING AND DEVELOPMENT OF [***] INHIBITORS (the “Agreement”) is effective as of this day of October 2018 (the “Effective Date”) by and between Immunic AG, a stock corporation organized under the laws of Germany, having a place of business at Am Klopferspitz 19, 82152 Martinsried, Germany (“Immunic”), and Daiichi Sankyo Co., Ltd., a Japanese corporation organized under the laws of Japan, having a place of business at 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan (“DS)”; Immunic and DS are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties”).
REDACTEDAsset Purchase Agreement • July 17th, 2019 • Immunic, Inc. • Pharmaceutical preparations
Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.
